|
Jul 30
|
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
|
|
Jul 26
|
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
|
|
Jul 26
|
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
|
|
Jan 22
|
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
|
|
Dec 20
|
ProMIS Neurosciences Announces Publication on Novel Target for ALS
|
|
Nov 14
|
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
|
|
Aug 21
|
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
|
|
Jun 29
|
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
|